Download Free Sample
Author
Manoj Kumar is a postgraduate in Life Sciences with over seven years of dedicated experience in the fields of anima.....
Swine, Ruminant and Companion Animals Vaccines Market: By Product, By Disease and Region Forecast 2019-2030
Swine, Ruminant and Companion Animals Vaccines Market: By Product, By Disease and Region Forecast 2019-2030
Swine, ruminant and companion animal vaccines market size was valued at US$ 4,656.6 million in 2023, and is poised to grow at a CAGR of 6.1% from 2024 to 2030. The swine, ruminant, and companion animal vaccines market is expected to experience steady growth due to increased pet ownership in developed countries and a rise in the number of cattle & poultry in developing countries. Furthermore, the rise in investment in research and development of vaccines, which inhibit the growth of antibiotic-resistant organisms, boosts the growth of the swine, ruminant, and companion animal vaccines market. Productivity in livestock is severely impacted by the presence of a few bacterial, viral, and protozoan borne diseases. Timely vaccination prevents the risk of infection and affects a farmers income through livestock rearing. Furthermore, the rate of developing infectious diseases continues to rise, necessitating the rapid deployment of new vaccinations.
For effective disease eradication, it is critical to identify such diseases and vaccinate animals regularly. Because of advancements in technology and medicine and our comprehensive knowledge of immunology, molecular biology, microbiology, and biochemistry, among other basic science fields, new vaccine manufacturing methods have emerged, providing several chances to key market players. In the swine, ruminant, and companion animal vaccines market size, the attenuated vaccines segment dominated the product type segment with the largest share. By stimulating a wide spectrum of immune responses, attenuated vaccines can deliver better immunity than conventional vaccines. Furthermore, it helps to lessen the need for booster vaccinations that can be given orally and generates long-lasting and fast immunity, all of which contribute to the growth of the swine, ruminant, and companion animal vaccines market.
Study Period
2024-2030Base Year
2023CAGR
6.1%Largest Market
North AmericaFastest Growing Market
Europe
The rising prevalence of zoonotic illnesses could negatively influence human health, driving up demand for swine, ruminant, and companion animal vaccines. Human and animal health are increasingly threatened by emerging and exotic animal illnesses, undermining food security. Furthermore, the lack of animal health awareness and the potential for adverse effects of veterinary vaccinations on human and other animal health limit the market's growth.
In 2022, North America led the market and held a bigger share. The high incidence of livestock and zoonotic illnesses, which result in large-scale animal mortality, can be blamed for this enormous share. Furthermore, due to the large number of well-established pharmaceutical companies that are continually attempting to expand their geographical reach and commercialize their vaccines, the market is expected to grow. In addition, the increased prevalence of canine illnesses, which is driving up vaccination adoption, and the growing pet population in the United States are two significant factors driving the regional market forward.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2024-2030 |
|
Market Size in 2023 |
US$ 4,656.6 million |
|
Market CAGR |
6.1% |
|
By Product Type |
|
|
By Disease |
|
|
By Region |
|
Download Free Sample Report
Swine, ruminant and companion animal vaccines market size was valued at US$ 4,656.6 million in 2023, and is set to grow at a CAGR of 6.1% from 2024-2030.
The major players in the global swine, ruminant, and companion animals vaccines market are ??? Boehringer Ingelheim International GmbH., IDT Biologika GmbH, HIPRA, Ceva Sante Animale, Elanco, Arko Laboratories Ltd, Merial, Vetoquinol, Zoetis Inc., Phibro Animal Health Corporation, Merck & Co., Inc., and Virbac.
Europe is the fastest-growing region for Swine, Ruminant and Companion Animals Vaccines Market
| 1. Executive Summary |
| 2. Global Swine, Ruminant and Companion Animals Vaccines Market Introduction |
| 2.1. Global Swine, Ruminant and Companion Animals Vaccines Market Taxonomy |
| 2.2. Global Swine, Ruminant and Companion Animals Vaccines Market Definitions |
| 2.2.1. By Product |
| 2.2.2. By Disease |
| 2.2.3. By Region |
| 3. Global Swine, Ruminant and Companion Animals Vaccines Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Swine, Ruminant and Companion Animals Vaccines Market Dynamic Factors - Impact Analysis |
| 4. Global Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 |
| 4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Swine, Ruminant and Companion Animals Vaccines Market, By Product, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1. Swine Vaccine |
| 5.1.1. Inactivated Vaccines |
| 5.1.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.1.3. Market Opportunity Analysis |
| 5.1.2. Live Attenuated Vaccines |
| 5.1.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.2.3. Market Opportunity Analysis |
| 5.1.3. Others |
| 5.1.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3.3. Market Opportunity Analysis |
| 5.2. Cattle Vaccine |
| 5.2.1. Toxoid |
| 5.2.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.1.3. Market Opportunity Analysis |
| 5.2.2. Recombinant |
| 5.2.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.2.3. Market Opportunity Analysis |
| 5.2.3. Inactivated |
| 5.2.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3.3. Market Opportunity Analysis |
| 5.3. Companion Animal Vaccines |
| 5.3.1. Attenuated Live Vaccine |
| 5.3.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.1.3. Market Opportunity Analysis |
| 5.3.2. Inactivated Vaccine |
| 5.3.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.2.3. Market Opportunity Analysis |
| 5.3.3. Others |
| 5.3.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 5.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3.3. Market Opportunity Analysis |
| 6. Global Swine, Ruminant and Companion Animals Vaccines Market, By Disease, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1. Swine Disease |
| 6.1.1. Diarrhea |
| 6.1.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.1.3. Market Opportunity Analysis |
| 6.1.2. Swine Influenza |
| 6.1.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.2.3. Market Opportunity Analysis |
| 6.1.3. Bordetella Rhinitis |
| 6.1.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3.3. Market Opportunity Analysis |
| 6.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS) |
| 6.1.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.4.3. Market Opportunity Analysis |
| 6.1.5. Porcine Circovirus Associated Disease (PCVAD) |
| 6.1.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.5.3. Market Opportunity Analysis |
| 6.1.6. Other Diseases |
| 6.1.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.1.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.6.3. Market Opportunity Analysis |
| 6.2. Cattle Diseases |
| 6.2.1. FMD |
| 6.2.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.1.3. Market Opportunity Analysis |
| 6.2.2. Infectious Respiratory Diseases |
| 6.2.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.2.3. Market Opportunity Analysis |
| 6.2.3. Reproductive Disorders |
| 6.2.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3.3. Market Opportunity Analysis |
| 6.2.4. Others |
| 6.2.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.2.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.4.3. Market Opportunity Analysis |
| 6.3. Companion Animal Diseases |
| 6.3.1. Rabies |
| 6.3.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.1.3. Market Opportunity Analysis |
| 6.3.2. Hepatitis |
| 6.3.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.2.3. Market Opportunity Analysis |
| 6.3.3. Leukemia |
| 6.3.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3.3. Market Opportunity Analysis |
| 6.3.4. Others |
| 6.3.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 6.3.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.4.3. Market Opportunity Analysis |
| 7. Global Swine, Ruminant and Companion Animals Vaccines Market Forecast, By Region, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Middle East and Africa |
| 7.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 7.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 7.6. Global Swine, Ruminant and Companion Animals Vaccines Market - Opportunity Analysis Index, By Product, Disease, and Region, 2024 - 2030 |
| 8. North America Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 8.1. Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Swine Vaccine |
| 8.1.1.1. Inactivated Vaccines |
| 8.1.1.2. Live Attenuated Vaccines |
| 8.1.1.3. Others |
| 8.1.2. Cattle Vaccine |
| 8.1.2.1. Toxoid |
| 8.1.2.2. Recombinant |
| 8.1.2.3. Inactivated |
| 8.1.3. Companion Animal Vaccines |
| 8.1.3.1. Attenuated Live Vaccine |
| 8.1.3.2. Inactivated Vaccine |
| 8.1.3.3. Others |
| 8.2. Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Swine Diseases |
| 8.2.1.1. Diarrhea |
| 8.2.1.2. Swine Influenza |
| 8.2.1.3. Bordetella Rhinitis |
| 8.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS) |
| 8.2.1.5. Porcine Circovirus Associated Disease (PCVAD) |
| 8.2.1.6. Other Diseases |
| 8.2.2. Cattle Diseases |
| 8.2.2.1. FMD |
| 8.2.2.2. Infectious Respiratory Diseases |
| 8.2.2.3. Reproductive Disorders |
| 8.2.2.4. Others |
| 8.2.3. Companion Animal Diseases |
| 8.2.3.1. Rabies |
| 8.2.3.2. Hepatitis |
| 8.2.3.3. Leukemia |
| 8.2.3.4. Others |
| 8.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. USA |
| 8.3.2. Canada |
| 8.4. North America Swine, Ruminant and Companion Animals Vaccines Market - Opportunity Analysis Index, By Product, Disease, and Country, 2024 - 2030 |
| 8.5. North America Swine, Ruminant and Companion Animals Vaccines Market Dynamics Trends |
| 9. Europe Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 9.1. Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Swine Vaccine |
| 9.1.1.1. Inactivated Vaccines |
| 9.1.1.2. Live Attenuated Vaccines |
| 9.1.1.3. Others |
| 9.1.2. Cattle Vaccine |
| 9.1.2.1. Toxoid |
| 9.1.2.2. Recombinant |
| 9.1.2.3. Inactivated |
| 9.1.3. Companion Animal Vaccines |
| 9.1.3.1. Attenuated Live Vaccine |
| 9.1.3.2. Inactivated Vaccine |
| 9.1.3.3. Others |
| 9.2. Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Swine Diseases |
| 9.2.1.1. Diarrhea |
| 9.2.1.2. Swine Influenza |
| 9.2.1.3. Bordetella Rhinitis |
| 9.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS) |
| 9.2.1.5. Porcine Circovirus Associated Disease (PCVAD) |
| 9.2.1.6. Other Diseases |
| 9.2.2. Cattle Diseases |
| 9.2.2.1. FMD |
| 9.2.2.2. Infectious Respiratory Diseases |
| 9.2.2.3. Reproductive Disorders |
| 9.2.2.4. Others |
| 9.2.3. Companion Animal Diseases |
| 9.2.3.1. Rabies |
| 9.2.3.2. Hepatitis |
| 9.2.3.3. Leukemia |
| 9.2.3.4. Others |
| 9.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. France |
| 9.3.4. Spain |
| 9.3.5. Italy |
| 9.3.6. Russia |
| 9.3.7. Rest of Europe |
| 9.4. Europe Swine, Ruminant and Companion Animals Vaccines Market - Opportunity Analysis Index, By Product, Disease, and Country, 2024 - 2030 |
| 9.5. Europe Swine, Ruminant and Companion Animals Vaccines Market Dynamics Trends |
| 10. Asia-Pacific Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 10.1. Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Swine Vaccine |
| 10.1.1.1. Inactivated Vaccines |
| 10.1.1.2. Live Attenuated Vaccines |
| 10.1.1.3. Others |
| 10.1.2. Cattle Vaccine |
| 10.1.2.1. Toxoid |
| 10.1.2.2. Recombinant |
| 10.1.2.3. Inactivated |
| 10.1.3. Companion Animal Vaccines |
| 10.1.3.1. Attenuated Live Vaccine |
| 10.1.3.2. Inactivated Vaccine |
| 10.1.3.3. Others |
| 10.2. Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Swine Diseases |
| 10.2.1.1. Diarrhea |
| 10.2.1.2. Swine Influenza |
| 10.2.1.3. Bordetella Rhinitis |
| 10.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS) |
| 10.2.1.5. Porcine Circovirus Associated Disease (PCVAD) |
| 10.2.1.6. Other Diseases |
| 10.2.2. Cattle Diseases |
| 10.2.2.1. FMD |
| 10.2.2.2. Infectious Respiratory Diseases |
| 10.2.2.3. Reproductive Disorders |
| 10.2.2.4. Others |
| 10.2.3. Companion Animal Diseases |
| 10.2.3.1. Rabies |
| 10.2.3.2. Hepatitis |
| 10.2.3.3. Leukemia |
| 10.2.3.4. Others |
| 10.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. China |
| 10.3.2. India |
| 10.3.3. Japan |
| 10.3.4. ASEAN |
| 10.3.5. Australia & New Zealand |
| 10.3.6. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Swine, Ruminant and Companion Animals Vaccines Market - Opportunity Analysis Index, By Product, Disease, and Country, 2024 - 2030 |
| 10.5. Asia-Pacific Swine, Ruminant and Companion Animals Vaccines Market Dynamics Trends |
| 11. Latin America Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 11.1. Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Swine Vaccine |
| 11.1.1.1. Inactivated Vaccines |
| 11.1.1.2. Live Attenuated Vaccines |
| 11.1.1.3. Others |
| 11.1.2. Cattle Vaccine |
| 11.1.2.1. Toxoid |
| 11.1.2.2. Recombinant |
| 11.1.2.3. Inactivated |
| 11.1.3. Companion Animal Vaccines |
| 11.1.3.1. Attenuated Live Vaccine |
| 11.1.3.2. Inactivated Vaccine |
| 11.1.3.3. Others |
| 11.2. Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Swine Diseases |
| 11.2.1.1. Diarrhea |
| 11.2.1.2. Swine Influenza |
| 11.2.1.3. Bordetella Rhinitis |
| 11.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS) |
| 11.2.1.5. Porcine Circovirus Associated Disease (PCVAD) |
| 11.2.1.6. Other Diseases |
| 11.2.2. Cattle Diseases |
| 11.2.2.1. FMD |
| 11.2.2.2. Infectious Respiratory Diseases |
| 11.2.2.3. Reproductive Disorders |
| 11.2.2.4. Others |
| 11.2.3. Companion Animal Diseases |
| 11.2.3.1. Rabies |
| 11.2.3.2. Hepatitis |
| 11.2.3.3. Leukemia |
| 11.2.3.4. Others |
| 11.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Rest of Latin America |
| 11.4. Latin America Swine, Ruminant and Companion Animals Vaccines Market - Opportunity Analysis Index, By Product, Disease, and Country, 2024 - 2030 |
| 11.5. Latin America Swine, Ruminant and Companion Animals Vaccines Market Dynamics Trends |
| 12. Middle East and Africa Swine, Ruminant and Companion Animals Vaccines Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030 (Revenue, USD Mn) |
| 12.1. Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Swine Vaccine |
| 12.1.1.1. Inactivated Vaccines |
| 12.1.1.2. Live Attenuated Vaccines |
| 12.1.1.3. Others |
| 12.1.2. Cattle Vaccine |
| 12.1.2.1. Toxoid |
| 12.1.2.2. Recombinant |
| 12.1.2.3. Inactivated |
| 12.1.3. Companion Animal Vaccines |
| 12.1.3.1. Attenuated Live Vaccine |
| 12.1.3.2. Inactivated Vaccine |
| 12.1.3.3. Others |
| 12.2. Disease Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1. Swine Diseases |
| 12.2.1.1. Diarrhea |
| 12.2.1.2. Swine Influenza |
| 12.2.1.3. Bordetella Rhinitis |
| 12.2.1.4. Porcine Reproductive and Respiratory Syndrome (PRRS) |
| 12.2.1.5. Porcine Circovirus Associated Disease (PCVAD) |
| 12.2.1.6. Other Diseases |
| 12.2.2. Cattle Diseases |
| 12.2.2.1. FMD |
| 12.2.2.2. Infectious Respiratory Diseases |
| 12.2.2.3. Reproductive Disorders |
| 12.2.2.4. Others |
| 12.2.3. Companion Animal Diseases |
| 12.2.3.1. Rabies |
| 12.2.3.2. Hepatitis |
| 12.2.3.3. Leukemia |
| 12.2.3.4. Others |
| 12.3. Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Gulf Cooperation Council (GCC) Countries |
| 12.3.2. South Africa |
| 12.3.3. Rest of MEA |
| 12.4. MEA Swine, Ruminant and Companion Animals Vaccines Market - Opportunity Analysis Index, By Product, Disease, and Country, 2024 - 2030 |
| 12.5. MEA Swine, Ruminant and Companion Animals Vaccines Market Dynamics Trends |
| 13. Competition Landscape |
| 13.1. Strategic Dashboard of Top Market Players |
| 13.2. Company Profiles (Introduction, Financial Analysis, Product Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 13.2.1. Boehringer Ingelheim International GmbH. |
| 13.2.2. IDT Biologika GmbH |
| 13.2.3. HIPRA |
| 13.2.4. Ceva Sante Animale |
| 13.2.5. Elanco |
| 13.2.6. Arko Laboratories Ltd |
| 13.2.7. Merial |
| 13.2.8. Vetoquinol |
| 13.2.9. Zoetis Inc. |
| 13.2.10. Phibro Animal Health Corporation |
| 13.2.11. Merck & Co., Inc. |
| 13.2.12. Virbac |
| 14. Research Methodology |
| 15. Key Assumptions and Acronyms |
Key Market Players
Author
Manoj Kumar is a postgraduate in Life Sciences with over seven years of dedicated experience in the fields of animal health and agriculture. His passion lies in unraveling the complexities of these domains through rigorous research and practical insights. Manoj Kumar’s journey has been marked by several key achievements: as a market analyst and competitive intelligence expert, he dissects data to provide actionable insights for global clients. Simultaneously, he champions animal healthcare, diagnosing ailments, and designing preventive care strategies. In the realm of agriculture, his focus on sustainable practices, emphasizing crop nutrition, soil health, and precision agriculture. His holistic approach and commitment to advancing science make him a respected figure in the ever-evolving landscape of life sciences.